Martin Tolar, MD, PhD, is the Founder, President, and CEO of Alzheon, a company dedicated to developing treatments for Alzheimer's disease and other neurodegenerative disorders. With a rich background in neurology and neuroscience, Dr. Tolar has led Alzheon to significant milestones in Alzheimer's research. His leadership and expertise have positioned Alzheon at the forefront of innovative therapeutic interventions.
Martin Tolar's Email & LinkedIn
You can also contact Martin Tolar through his LinkedIn.
If you want to find further information about Martin Tolar, like his phone number, or other people working at Alzheon, sign up to Clay.
Who is the CEO of Alzheon?
Dr. Martin Tolar, MD, PhD, is a distinguished figure in the field of neurology and neuroscience, currently serving as the President, CEO, and Founder of Alzheon Inc. Dr. Tolar has held several prominent positions in the life sciences industry, including executive roles at Knome, Inc., NormOxys, Inc., and CoMentis, Inc. He has also contributed to academia as an Assistant Professor in the Department of Neurology at Yale University School of Medicine.
Under his leadership, Alzheon has made significant strides in Alzheimer's research, particularly with the development of ALZ-801, a promising treatment for the disease. Dr. Tolar's career is marked by a commitment to advancing therapeutic interventions for neurodegenerative disorders.
Work History
Dr. Martin Tolar, MD, PhD, has an extensive and impressive work history in the field of neurology and neuroscience. Here is a detailed list of his professional experience:
- INDRC - International Neurodegenerative Disorders Research Center - Founder, Chairman of Executive Board (2021 - Present)
- Alzheon, Inc. - Founder, President & CEO (2013 - Present)
- Alzheimer's Drug Discovery Foundation - Business Advisory Board & Scientific Review Board (2013 - Present)
- The Alzheimer Foundation - Scientific Board (2011 - Present)
- Advance Healthcare Management Institute - Academic Board (2009 - Present)
- Bellus Health - Board of Directors (2010 - 2017)
- Knome, Inc. - President & CEO (2011 - 2013)
- Suven Life Sciences Ltd. - Board of Directors (2007 - 2013)
- NormOxys, Inc. - President & CEO (2009 - 2011)
- CoMentis, Inc. - Executive Vice President & Chief Business Officer (2008 - 2009)
- CoMentis, Inc. - Chief Scientific Officer (2007 - 2008)
- Pfizer - Worldwide Business Development (2005 - 2007)
- Pfizer - Neuroscience Clinical Development (2001 - 2005)
- Yale University School of Medicine - Assistant Professor (2002 - 2007)
Education History
Dr. Martin Tolar, MD, PhD, has a diverse and robust educational background that spans multiple disciplines and prestigious institutions. He began his academic journey at the Czech Technical University in Prague, where he studied Computer Science from 1982 to 1987. He then pursued a medical degree at Charles University, earning his MD in Medicine between 1985 and 1991. Dr. Tolar further specialized in Neuroscience, obtaining a PhD from the University of Cincinnati College of Medicine from 1992 to 1997. Following his PhD, he completed a Residency in Neurology at Boston Medical Center from 1998 to 2001. To round out his education, Dr. Tolar attended the University of Michigan's Stephen M. Ross School of Business for an Executive Management program from 2005 to 2006.
When did Martin Tolar, MD, PhD join Alzheon?
Martin Tolar, MD, PhD, founded Alzheon, Inc. in January 2013 and has been serving as its President and CEO since its inception. With a decade-long tenure at Alzheon, Dr. Tolar has been instrumental in steering the company towards significant advancements in Alzheimer's research and treatment. His leadership has been pivotal in the development of ALZ-801, a promising therapeutic intervention for Alzheimer's disease. Over the past ten years, Dr. Tolar's commitment to innovative therapeutic solutions has solidified Alzheon's position at the forefront of neurodegenerative disorder research.